Research Site

Montreal H3T 1E2

2 studies enrolling now · 22 studies all time

What they study most

Advanced Clear Cell Renal Cell Carcinoma, Advanced Upper Gastrointestinal Tract Adenocarcinoma, Breast Cancer, Breast Neoplasms, Cerebral Stroke, Cerebrovascular Stroke, Choroideremia, Chronic Lymphocytic Leukemia, Colorectal Cancer, Diabetes Mellitus, Type 2, ER-Positive HER2-Negative Breast Cancer, Esophagogastric Junction

Studies at this site

• Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma — Recruiting now
• Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) — Recruiting now
• A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body — Running, not enrolling
• A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL — Running, not enrolling
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer — Running, not enrolling
• A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors — Running, not enrolling
• Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer — Running, not enrolling
• Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency — Running, not enrolling
• Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer — Running, not enrolling
• A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease — Running, not enrolling
• Efficacy and Safety of BIIB111 for the Treatment of Choroideremia — Completed
• Natural History of the Progression of Choroideremia Study — Completed
• BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) — Completed
• First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX — Completed
• Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis — Completed
• Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis — Completed
• A Study of Monthly Risedronate for Osteoporosis — Completed
• A Trial Comparing the Efficacy and Tolerability of Faslodex With Nolvadex in Postmenopausal Women With Advanced Breast Cancer — Completed
• Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer — Completed
• GALLANT 6 Tesaglitazar vs. Pioglitazone — Stopped early
• Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke — Completed
• GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes — Completed